State University of New York - Upstate Medical University
Who can join
Adults 5 to 13, any sex, with Problem Behavior. Patients with the condition only — healthy volunteers not accepted.
Results — posted to ClinicalTrials.gov
Per-arm endpoint measurements with 95% confidence intervals where reported. Source: trial results section.
Averge of Aappropriate Communication ResponsesPrimary· Participants were seen 3-5 days/week for a 60-min visit. Second-by-second data were collected over a period of successive, 5-min (300 s) sessions conducted consecutively during the visit. The unit of analysis was mean responding during the 5-min session.
Appropriate communication responses for each participant will be selected based on language level as identified via the Peabody Picture Vocabulary Test, 4th edition (PPVT-4) and/or the Expressive Vocabulary Test-3rd edition (EVT-3)
Group
Value
95% CI
Functional Communication Training (FCT)
3.33
1.27 – 4.4
Average of Problem Behavior ResponsesPrimary· Participants were seen 3-5 days/week for a 60-min visit. Second-by-second data were collected over a period of successive, 5-min (300 s) sessions conducted consecutively during the visit. The unit of analysis was mean responding during the 5-min session.
Individualized operational definitions of problem behavior and communication were developed for each participant. These included aggression, disruption, self-injurious behavior. Communication included card exchanges, manual signs, card touches, and augmentative device responding. These behaviors were measured via direct observation and data were analyzed by visual inspection.
Group
Value
95% CI
Functional Communication Training (FCT)
0.48
0 – 10.4
Sponsor's own description
This project examines mechanisms to address two significant challenges present in communication-based behavioral interventions for individuals with autism and comorbid severe destructive behavior (SDB): (a) inflexible communication responding and (b) reemergence of severe destructive behavior when challenges to treatment integrity occur. Achieving the proposed aims will advance clinical practice related to the treatment of SDB and generalization of treatment effects to mitigate against the resurgence of SDB
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
NCT05928247 — Manualized Assessment and Treatment Model of Challenging Behavior
· NA
· recruiting
NCT06651606 — Preventing Relapse of Problem Behavior Through Behavioral Economics: A Translational Analysis
· NA
· recruiting
NCT05925101 — Basic and Applied Research on Extinction Bursts
· NA
· recruiting
NCT05537610 — Extensions of Resurgence as Choice
· NA
· recruiting
NCT05649839 — Design of a Prototype Garment Adapted to Demented Elderly Subjects With Disturbing Behavioral Problems in the Management
· NA
· active not recruiting
Other State University of New York - Upstate Medical University trials
Trials by the same sponsor.
NCT07220031 — Effect of Activated Charcoal on Serum Osmolality, Osmolal Gap, and Enzymatic Ethylene Glycol Assay
· not yet recruiting
NCT04736953 — Sirolimus Treatment Of Patients With SLE
· Phase 2
· not yet recruiting
NCT06370442 — Intranasal Dexmedetomidine vs. Standard of Care for Emergency Department (ED) Procedural Sedation in the Older Adult
· Phase 3
· not yet recruiting
NCT06045650 — Relationship Between Oxytocin Level, Trust, and Attachment in Individuals With Borderline Personality Disorder
· not yet recruiting
NCT05967455 — Homologous Re-infection With Dengue 1 or Dengue 3
· Phase 1
· completed
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by State University of New York - Upstate Medical University
Last refreshed: 5 March 2026
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05918393.